Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
| 110.32 | |
| 110.04 | |
| - | |
| 110.67 | |
| 109.67 | |
| 88.3282-112.48 | |
| 222 846 M | |
| 22.5092 | |
| 2 025 M | |
| 48 860 M | |
| 1.97 | |
| 0.0344 | |
| 0.491 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
We expect Incyte Corporation INCY to surpass expectations when it reports second-quarter 2024 results on Jul 30, before the opening bell. Let’s see how things have shaped up for the quarter to be r...
Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter. We know ea...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
